In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Boehringer Ingelheim, Pfizer to co-promote Spiriva

Executive Summary

Boehringer Ingelheim and Pfizer will globally co-promote BI's Spiriva (tiotropium), a once daily, inhaled bronchodilator to treat chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis and emphysema. Smoking mostly causes the disorder, which causes permanent damage to lung tissue. According to a source from BI, the term of the contract will probably be less than eight years.
Deal Industry
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register